
AADI
Healthcare · Biotechnology · $94.9M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2025
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 11, 2025 | Before the open | -0.29 | -0.67 | -127.1% |
| Nov 6, 2024 | Before the open | -0.46 | -0.46 | 0.0% |
| Aug 7, 2024 | Before the open | -0.69 | -0.54 | +21.7% |
| May 8, 2024 | Before the open | -0.64 | -0.68 | -6.3% |
| Mar 13, 2024 | Before the open | -0.65 | -0.60 | +7.7% |
| Nov 8, 2023 | Before the open | -0.72 | -0.60 | +16.7% |
| Aug 9, 2023 | Before the open | -0.62 | -0.67 | -8.1% |
| May 10, 2023 | Before the open | -0.58 | -0.57 | +1.7% |
| Mar 28, 2023 | Before the open | -0.71 | -0.52 | +26.8% |
| Nov 9, 2022 | Before the open | -0.74 | -0.68 | +8.1% |
| Aug 10, 2022 | Before the open | -0.75 | -0.87 | -16.0% |
| May 12, 2022 | Before the open | -0.71 | -0.66 | +7.0% |
| Mar 17, 2022 | Before the open | -0.98 | -0.77 |
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is…
| +21.4% |
| Nov 10, 2021 | Before the open | -0.66 | -1.36 | -106.1% |
| Aug 11, 2021 | After the close | -6.00 | -1.35 | +77.5% |
| May 17, 2021 | Before the open | -1.35 | -1.35 | 0.0% |
| Mar 11, 2021 | Before the open | -2.02 | -1.50 | +25.7% |
| Nov 10, 2020 | Before the open | -2.10 | -1.80 | +14.3% |
| Aug 12, 2020 | Before the open | 0.27 | 0.23 | -14.8% |
| May 7, 2020 | Before the open | -0.09 | -0.10 | -11.1% |
| Mar 16, 2020 | Before the open | -1.80 | -1.65 | +8.3% |
| Nov 7, 2019 | Before the open | -1.87 | -1.65 | +11.8% |
| Aug 8, 2019 | Before the open | -2.40 | -1.80 | +25.0% |
| May 9, 2019 | Before the open | -3.30 | -3.15 | +4.5% |
| Mar 5, 2019 | Before the open | -3.37 | -3.15 | +6.5% |
| Nov 7, 2018 | Before the open | 4.30 | 4.20 | -2.3% |
| Aug 14, 2018 | Before the open | -3.37 | -3.30 | +2.1% |
| May 15, 2018 | Before the open | -0.23 | -0.27 | -17.4% |
| Mar 13, 2018 | After the close | — | -0.23 | — |